Zacks: Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Recommendation of “Strong Buy” from Analysts

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1-year consensus target price of $29.63 for the company and are expecting that the company will post ($0.48) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Milestone Pharmaceuticals an industry rank of 60 out of 256 based on the ratings given to its competitors.

A number of research firms have weighed in on MIST. Oppenheimer began coverage on Milestone Pharmaceuticals in a research note on Tuesday, June 4th. They issued an “outperform” rating and a $32.00 target price on the stock. CIBC began coverage on Milestone Pharmaceuticals in a research report on Tuesday, June 4th. They set an “outperform” rating and a $32.00 price target on the stock. Cowen began coverage on Milestone Pharmaceuticals in a research report on Monday, June 3rd. They set an “outperform” rating and a $32.00 price target on the stock. Piper Jaffray Companies began coverage on Milestone Pharmaceuticals in a research report on Monday, June 3rd. They set an “overweight” rating and a $26.50 price target on the stock. Finally, Jefferies Financial Group began coverage on Milestone Pharmaceuticals in a research report on Monday, June 3rd. They set a “buy” rating and a $28.00 price target on the stock.

In other news, major shareholder Rtw Investments, Lp purchased 666,667 shares of the company’s stock in a transaction dated Thursday, May 9th. The shares were acquired at an average price of $15.00 per share, with a total value of $10,000,005.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Holdings A/S Novo acquired 333,333 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,999,995.00. The disclosure for this purchase can be found here.

MIST stock traded down $2.13 during midday trading on Friday, reaching $21.00. The company’s stock had a trading volume of 18,887 shares, compared to its average volume of 32,985. The company’s fifty day moving average price is $21.38. Milestone Pharmaceuticals has a 1 year low of $15.09 and a 1 year high of $27.95.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Recommended Story: Balanced Fund

Get a free copy of the Zacks research report on Milestone Pharmaceuticals (MIST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.